Recursion Pharmaceuticals filed a prospectus supplement to register for resale 3,225,902 shares of their Class A common stock issued to Tempus Labs as part of a Master Agreement.
AI Assistant
RECURSION PHARMACEUTICALS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.